

Amendments to the Claims:

This Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1 – 24. (Canceled)

25. (Currently amended) An isolated recombinant polypeptide comprising: ~~a member selected from the group consisting of~~

(a) the amino acid sequence SEQ ID NO:2 ~~or;~~ and

(b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition, which can include an adjuvant[[],] or coupling to a suitable carrier ~~coupled to the polypeptide~~, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.

26. (Canceled)

27. (Currently amended) The isolated recombinant polypeptide of claim 25, wherein the polypeptide is according to (a) comprises the amino acid sequence SEQ ID NO:2.

28. (Canceled)

29. (Currently amended) The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises ~~is according to (b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or coupling to a suitable carrier, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.~~

30. (Canceled)

31. (Currently amended) The isolated recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition, which can include an adjuvant[[],] or coupling to a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.

32. (Currently amended) The isolated recombinant polypeptide of ~~Claim~~ claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33 - 34. (Canceled)

35. (Currently amended) A An isolated recombinant fusion protein comprising the ~~isolated~~ polypeptide of ~~Claim~~ claim 25.

36 - 39. (Canceled)

40. (Currently amended) An immunogenic composition comprising the recombinant polypeptide of ~~Claim~~ claim 25 and a pharmaceutically acceptable carrier.

41. (Currently amended) The immunogenic composition of ~~Claim~~ claim 40, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen.

42. (Cancelled)

43. (Currently amended) A method for inducing an immune response in a mammal comprising administration of the isolated recombinant polypeptide of ~~Claim~~ claim 25.

44 - 47. (Canceled)

48. (Currently amended) A An isolated recombinant fusion protein comprising the isolated polypeptide of Claim claim 27.

49. (Currently amended) An immunogenic composition comprising the isolated recombinant polypeptide of Claim claim 27.

50. (Currently amended) A An isolated recombinant fusion protein comprising the isolated polypeptide of Claim claim 29.

51. (Currently amended). An immunogenic composition comprising the isolated recombinant polypeptide of Claim claim 29.

52 - 56 (canceled)

57. (New) An isolated recombinant fusion protein comprising the polypeptide of claim 31.

58. (New) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25.

59. (New) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31.